AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Our lead compound, AZP2006, is currently in clinical phase 1

Multiple ascending dose study in healthy volunteers is ongoing. These studies show that AZP2006 was well tolerated.


Read more

Targeted therapeutical areas

Read more

AlzProtect, starts a collaboration with PAREXEL Biotech for phase 2a of AZP2006 for the treatment...

March, 21 2019 Read more

February, 18 2019 Read more